Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Management of COVID-19 in Patients with Pulmonary Arterial Hypertension

Ioannis T. Farmakis, MD, MSc, George Giannakoulas, MD, PhD

INTRODUCTION

The COVID-19 pandemic has caused more than 6 million deaths worldwide as of April 2022, while model data suggest that the toll of the pandemic on mortality could be at least three times greater. Early in the course of the pandemic, observational studies from China indicated that patients with comorbidities were particularly vulnerable to complications from the SARS-CoV-2 infection and at high risk for severe disease and mortality. Patients with a history of cardiovascular disease, diabetes, and cancer remain at increased risk for complications from COVID-19. In fact, nationwide inpatient data from Germany show that deceased hospitalized patients were more commonly elderly (≥70 years), with a higher Charlson comorbidity index compared with survivors, and were more likely to suffer from cardiovascular comorbidities (hypertension 52%, coronary artery disease 23%, and heart failure 31%).

On the other hand, pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality. In PAH, elevated pulmonary vascular resistance and the development of decompensated right heart response are eventually the key mechanisms leading to death for most of the patients. PAH-related hospitalizations amount to ~30 per million population annually and are associated with 6% inpatient mortality. A primary cardiac discharge diagnosis is recorded in almost half of the PAH-related hospitalizations, but primary cardiac hospitalizations show a decreasing trend from 2001 to 2014 falling from 52.9% to 41.4% of all hospitalizations. Extra-cardiac reasons for hospitalization in patients with PAH are overall associated with greater inpatient mortality than a primary cardiac diagnosis (6.9% vs 5.3%). Remarkably, a sepsis diagnosis is associated with a 25% risk for inpatient mortality, while pneumonia with 9.4% and respiratory insufficiency or arrest with 21.4%.

The aforementioned evidence and rationale suggest that patients with PAH could be at increased risk for complications and, subsequently, worse outcomes following COVID-19. In this review, we discuss the evidence regarding the course and the management of COVID-19 in patients with PAH, the challenges in PAH management during the pandemic and, lastly, the long-term complications of COVID-19 in relation to pulmonary vascular disease (Fig. 1).
EARLY EVIDENCE: COULD PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION HAVE FAVORABLE OUTCOMES DURING COVID-19 INFECTION?

Early studies in the course of the pandemic showed controversial results regarding the outcome of patients with PAH and suggested that the SARS-CoV-2 infection could have a favorable outcome in this population (Table 1). A case series of 13 patients from more than 32 US expert PH centers in late March 2020 showed that intubation was required only in 3 patients, while only one patient died. Similarly, in a case series of 4 patients in the Lombardy region of Italy, none of the patients developed acute right heart failure and all survived the disease. Lastly, a case series from Spain comprising 10 patients with PAH and COVID-19 (7 of them in a low-risk status) showed that 70% of patients required hospitalization, while none of them died, an unexpectedly favorable outcome. These results led the investigators to form hypotheses that certain pathophysiological features of PAH, as well as benefits attributed to the targeted medical PAH therapies could lead to a protective effect in COVID-19. The suggested mechanisms included reduced viral entrance through decreased angiotensin-converting enzyme (ACE)-2 expression in PAH, an attenuated response to lung perfusion changes due to basal abnormal lung perfusion in PAH and chronic vasodilator treatment, especially the protective effect of endothelin receptor antagonists against acute respiratory distress syndrome (ARDS).

FURTHER EVIDENCE

The largest study conducted comes from the French PH registry and included 211 patients with precapillary PH (among them 58.3% with a diagnosis of PAH) and a diagnosis of COVID-19 from February 2020 to April 2021. In this prospective cohort, 32.2% of patients were hospitalized in a common ward, while an additional 27.5% of patients were hospitalized in an intensive care unit (ICU); the median length of stay was 95–15 days. High-flow nasal cannula and corticosteroids were increasingly used after September 2020, while the proportion of patients receiving mechanical ventilation (11.1%) was similar between the 2 first waves of the pandemic. One-fourth of patients (24.6%) died (23% among group 1 PH), the proportion was 41.3% of hospitalized patients. Half of the patients who died and nearly a quarter of the hospitalized ones had documented limitations to care escalation (incl. do-not-resuscitate orders). The study was powered for limited inferential analysis regarding mortality; however, significant predictors of mortality were male sex, older age, and comorbidities (including chronic renal failure and chronic lung disease), which were more significant than the PH group per se.
| Study                        | Centers | Countries               | Study Period          | Population | N of patients | COVID-19 Incidence | Hospitalization Rate | Case Fatality Rate |
|-----------------------------|---------|-------------------------|-----------------------|------------|---------------|--------------------|----------------------|--------------------|
| Sulica et al, 2021          | 1 US    | March–May 2020          | PAH + CTEPH           | 11         | 3.1%          | 81.8%              | 45.4%                |
| Horn et al, 2020            | 32 US   | Late March 2020         | PAH                   | 13         | NR            | 53.8%              | 7.7%                 |
| Scuri et al, 2020           | 1 Italy | NR                      | PAH                   | 4          | NR            | 100%               | 0%                   |
| Nuche et al, 2020           | 1 Spain | Until 10 April 2020     | PAH                   | 10         | 2.9%          | 70%                | 0%                   |
| Belge et al, 2020           | 47      | 28 countries worldwide | 17 April 2020–10 May 2020 | PAH + CTEPH | 70 | NR             | 70%                  | 19%                 |
| Lee et al, 2020             | 58 US   | 17–24 April 2020        | PAH + CTEPH           | 50         | 0.29%         | 30%                | 12%                  |
| Farmakis et al, 2022        | 9 Greece| February 2020–August 2021 | PAH + CTEPH          | 18         | 3.6%          | 44.4%              | 22.2%                |
| Badagliacca et al, 2022     | 25 Italy| 1 March 2020–1 May 2020 | PAH                   | 20         | 0.46%         | 45%                | 45%                  |
| Godinas et al, 2021         | Patient survey | 52 countries worldwide | May–June 2020        | PAH + CTEPH | 9  | 1%              | NR                   | NR                  |
| Montani et al, 2022         | 26 France | February 2020–April 2021 | Precapillary PH      | 211        | 2.7%          | 59.7%              | 24.6%                |

**Abbreviations:** PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension.
Two large surveys conducted early in the pandemic, one led by European investigators and one from the US, provide more evidence and confirm such findings regarding the outcomes of COVID-19 in patients with PAH. In the survey of 47 PH centers from 28 countries worldwide (including 18 European countries), 70 COVID-19 cases were reported among PAH or chronic thromboembolic pulmonary hypertension (CTEPH) patients from 17 April 2020 to 10 May 2020. The median age of the cohort was 50 to 59 years and most patients (59%) were under a combination of targeted PAH therapies. The outcomes were not favorable for this PH cohort, since 46% were hospitalized in general wards, and 17% required ICU admission, while mortality was high (20%) for patients with PAH.

The US survey was conducted from 17 April 2020 to 1 May 2020 among 58 center directors of expert PH clinics. A total of 50 patients with PAH or CTEPH with recognized COVID-19 were reported; the cumulative incidence of COVID-19 among this population was similar to the concurrent at the time CDC population estimate of COVID-19 cumulative incidence in the general US population. The results were similar to the European cohort, since 30% of patients were hospitalized (22% in an ICU) and 12% of patients died.

We have recently conducted a study among 9 expert PH centers in Greece, cumulatively for 499 patients with PAH or CTEPH, covering a larger period of the pandemic, from late February 2020 (beginning of the pandemic in Greece) to late August 2021. We reported 18 cases with PAH or CTEPH and COVID-19, and among them 12 cases with PAH. The incidence risk of COVID-19 among the PH population was 3.6%, lower than the concurrent incidence risk of 4.8% among the Greek general population. In the PAH subgroup, the hospitalization rate was 33.3% and the mortality rate was 16.7% (2/12 patients). Of the 2 patients who died, one was greater than 75 years old with a history of cancer, while the other one had significant comorbidities. Both required long-term oxygen therapy at home, indicating the severity of the underlying disease.

Lastly, in an Italian nationwide multicenter survey, the incidence of COVID-19 during the first peak of the pandemic (March–May 2020) was comparable to the general population, however, mortality was 45% (9 patients out of 20 patients with confirmed SARS-CoV-2 infection in total).

Collectively, the aforementioned results indicate that the earlier data and the more recent observations do not match and that PAH is significant comorbidity that can lead to unfavorable outcomes during COVID-19 (see Table 1). In our opinion, additional comorbidities among patients with PAH (such as diabetes mellitus, obesity, and cardiopulmonary comorbidities), as well as advanced age, play an important role in the severity of the underlying pulmonary vascular pathology, perhaps even a larger one. Frailty has been shown to be a better predictor of disease outcomes in COVID-19 than age and comorbidities alone and we suggest that this also applies to the PAH population, whereby age, comorbidities, functional status, as well as the inherent PAH disease characteristics act synergistically to define prognosis. However, we must bear in mind that all of these studies were conducted during the prevaccination era, and also do not concern the Omicron variants. Thus, the characteristics of the pandemic are now changed and, therefore, different case fatality and hospitalization rates may apply to the PAH population as well.

MANAGEMENT OF SARS-CoV-2 INFECTION IN PULMONARY ARTERIAL HYPERTENSION

In general, SARS-CoV-2 infection in the context of PAH should be managed according to the current SARS-CoV-2 treatment guidelines; however, several considerations must be accounted for, especially when it comes to drug–drug interactions. All experts and societies agree that PAH-targeted medication should be continued in patients with PAH during the course of infection with SARS-CoV-2. Drug treatment should be continued irrespective of the severity of COVID-19 in patients with PAH to maintain clinical stability and avoid right heart decompensation.

Although patients with PAH are particularly vulnerable and comorbid, postexposure prophylaxis to SARS-CoV-2 with monoclonal antibodies is no longer recommended because the Omicron variant, which is now predominant in most countries, is not susceptible to them. The introduction of new antiviral therapies changed the landscape of the nonsevere (no need for oxygen or hospitalization) COVID-19 management for the general population, since drugs such as molnupiravir, nirmatrelvir-ritonavir, but also remdesivir, have received a conditional recommendation for patients who are at risk for progressing to severe COVID-19. However, nirmatrelvir-ritonavir is a strong CYP3A inhibitor and, therefore, coadministration with PDE5 inhibitors is prohibited and must be avoided because it increases the concentration of these PAH drugs. In addition, bosentan, riociguat, and calcium channel blockers may also have potential interactions and the coadministration is not recommended. On the other hand, no significant interactions are expected with the use of molnupiravir and PAH-targeted therapy.
The management of hospitalized and unstable patients with PAH and concomitant COVID-19 is particularly challenging as hypoxia and the systemic inflammatory response are difficult to treat. PAH-targeted drug treatment should be continued, although its composition or route of administration (for example i.v. for patients who cannot tolerate oral treatment or intubated patients) must be discussed with the PH expert team. The management of ventilation is difficult. In general, efforts must be concentrated to maintain an oxygen saturation greater than 90% and high-flow nasal cannula is an important ally toward that goal. However, in case of persistent hypercapnia, noninvasive ventilation may benefit patients, but it must be used with caution because it can further impair right ventricular function. Intubation should be discouraged in patients with PAH because of the high risk of death during the induction of general anesthesia. Maintaining a stable blood pressure (with systemic vaspressors), optimizing the fluid status (removal of excess fluids with diuretics or hemofiltration), and supporting the cardiac output (with careful use of inotropes) is of particular importance. Concerning COVID-19 specific treatment its use in patients with PAH and severe or critical COVID-19 is recommended. From September 2020 using data from the SOLIDARITY and RECOVERY trials systemic corticosteroids are strongly recommended for patients with severe or critical COVID-19. In addition, there is a strong recommendation for the use of interleukin-6 inhibitors (tocilizumab or sarilumab) in this group of patients.

The use of PAH-targeted medication in the treatment of COVID-19 in patients without baseline PAH has a theoretic basis due to the proven anti-inflammatory effects and reduction effects on pulmonary artery blood pressure, lung edema, and remodeling of drugs such as endothelin receptor antagonists, phosphodiesterase 5 inhibitors, riociguat and prostacyclin. However, their use is not yet studied in randomized trials. Concerning COVID-19 treatment its use in patients with PAH and severe or critical COVID-19 is recommended. From September 2020 using data from the SOLIDARITY and RECOVERY trials systemic corticosteroids are strongly recommended for patients with severe or critical COVID-19.

In addition, studies for the use of endothelin antagonists or PDE5 inhibitors in severe COVID-19 without baseline PAH are lacking. Only recently, a noncontrolled study of 25 patients with COVID-19 pneumonitis showed suggested good toleration of sildenafil, without hemodynamic, oxygenation, or dead space deterioration and amelioration in echocardiography and biomarkers.

Lastly, we should bear in mind that vaccination is the most effective way to prevent infection with SARS-CoV-2 and the potentially fatal and disabling complications of COVID-19. All patients with PAH should receive a primary and booster vaccination and follow the general vaccination planning recommendations as these will form in the future. Significant efforts should be made by the treating physicians to reassure patients and reduce their anxiety regarding the potential adverse effects of vaccines. No safety concerns in this particular subgroup of patients have been reported.

**PULMONARY ARTERIAL HYPERTENSION AMBULATORY TREATMENT DURING THE PANDEMIC**

Similar to other chronic diseases, the management of patients with PH in general, and PAH in particular, has been considerably challenging during the pandemic. The “exposure risk” of these vulnerable patients for routine follow-up, diagnostic or laboratory testing was high, especially in the earlier phases of the pandemic. In addition, the diagnostic pathway of incident PAH cases, as well as the initiation and up-titration of new PAH-targeted therapies during the pandemic was particularly challenging.

In a large survey among Italian centers, Badagliacca and colleagues observed a 71.4% reduction of in-person visits during the first 2 months of the pandemic (March–April 2020) compared with the same period in 2019 with a similar reduction to conducted paraclinical tests. A similar decline in patients visits, diagnostic testing, and overall clinic staffing was observed in a multicenter survey from the US. The most common reason for declining visits was a hospital/health system mandate, as well as the fear of patients and physicians for the contraction of COVID-19. In another worldwide survey conducted from 17 April 2020 to 10 May 2020, 8 out of 10 patients with either PAH or CTEPH were provided with a remote consultation (either by video- or tele-conferencing), whereas only 3% of them did not receive any consultation at all during this pandemic period.

COVID-19 has imposed a significant burden on the health care system and has subsequently caused a disruption of clinical care pathways for chronic diseases such as PAH. In PAH, it is important to maintain a close relationship between the patient and the caring PAH expert center, since tight monitoring and treatment titration is
mandated to achieve stratification in the low-risk category and avoid hazardous clinical outcomes. Especially in the earlier phases of the pandemic, it was important to streamline chronic outpatient care to achieve 2 goals: (i) offload physicians who dealt with the increasing workload in the inpatient service and (ii) protect patients from an environment of increased infection risk such as the outpatient health services. Telehealth programs exploit the advantage of video conference and have been introduced during the pandemic to remotely evaluate and monitor the symptoms and functional status of patients. Although telemonitoring does not permit a comprehensive physical examination or extensive diagnostic tests, it has been increasingly used, and according to our experience they help expert centers reach medical decisions regarding interventions and therapy titration. In a study from a Japanese referral PH center, telemedicine was effective in reducing travel distances and suggested that social networking-video calls may be useful, especially for patients who need advanced care, such as patients receiving parenteral prostanoids. However, older patients may experience difficulties adjusting to the new technologies and therefore more frequent, telephone visits, rather than video-call visits, would be desirable to reduce anxiety. The overall impact of the first waves of the pandemic on depression and anxiety in patients with PAH has been substantial, with problems stemming mostly from the fear of contracting COVID-19 and the difficulties in specialized care access.

Lately, in the new phases of the pandemic, which are characterized by vaccination coverage, including boosters, and also the dominance of the Omicron variant with subsequent milder forms of COVID-19, chronic care is gradually returning to prepandemic levels. It is to acknowledge though that the merits of telehealth may and should remain for particularly stable, low-risk patients and also when local outbreaks appear.

LONG-TERM COMPLICATIONS OF COVID-19 IN RELATION TO PULMONARY VASCULAR DISEASE IN PATIENTS WITHOUT BASELINE PULMONARY HYPERTENSION

The SARS-CoV-2 is a virus that shows great affinity to the endothelium and significant vascular changes have been described in patients with COVID-19. These vascular changes can affect both the macro- as well as the microvasculature, and are evident in the whole vascular wall, from the lumen to the perivascular regions, as a result of thrombotic in situ microangiopathy and a complex immune-inflammatory cascade. Some patients continue to experience symptoms following the acute phase of COVID-19, the so-called “long COVID” syndrome, pertaining to persistent damage in several organs, including the pulmonary vasculature. The changes observed in the lung vessels of patients with COVID-19 share many common features with the ones observed in patients with PH; namely, medial hypertrophy and smooth muscle cell proliferation. The prevalence of PH during the acute phase of COVID-19 is also high. In a study of 21 mechanically ventilated patients with COVID-19 who underwent right heart catheterization, low pulmonary vascular resistance, coherent with a blunted hypoxic vasoconstriction, high cardiac output and postcapillary pulmonary hypertension characterized the hemodynamic profile. In addition, there is a known increased incidence of pulmonary embolism, as well as in situ pulmonary thrombosis, in patients with COVID-19, as well as in those recovering from COVID-19, which could theoretically predispose to an increased incidence of chronic thromboembolic disease in the future. Taken together, these data have sparked the hypothesis that COVID-19 could predispose to the development of chronic PH. However, this is a subject of future investigation since long-term cohort studies are still lacking.

SUMMARY

PAH is serious comorbidity that can have a negative impact on the clinical outcomes related to COVID-19. Prognosis is determined by a combination of the underlying PAH disease features and risk stratification, along with other factors such as age, functional status, and comorbidities. The treatment of mild and severe COVID-19 in patients with PAH should follow the general recommendations, and PAH-targeted treatments should not be interrupted during the course of the disease. The epidemic has placed significant stress on PAH chronic care, prompting a move toward telemedicine. Finally, COVID-19 may increase the risk of developing chronic PH in patients without baseline PH; however, long-term evidence is currently scarce.

CLINICS CARE POINTS

- Nirmatrelvir-ritonavir is a strong CYP3A inhibitor and, therefore, coadministration with PAH drugs is prohibited and must be avoided.
PAH-targeted drug treatment should be continued, although its composition or route of administration must be discussed with the PH expert team.

High-flow nasal cannula is an important ally toward maintaining oxygen saturation in severe COVID-19. In case of persistent hypcapnia, noninvasive ventilation may benefit patients, but it must be used with caution. Intubation should be discouraged in patients with PAH because of the high risk of death.

Limitation of care is a case-by-case decision and not categorical.

FUNDING
None to declare.

Conflicts of interest.

AUTHORS’ CONTRIBUTION
I.T. Farmakis and G. Giannakoulas contributed to the conception or design of the work. IF and GG contributed to the acquisition, analysis, or interpretation of data for the work. IF drafted the article. GG critically revised the article. Both gave final approval and agreed to be accountable for all aspects of the work ensuring integrity and accuracy.

ACKNOWLEDGMENTS
None to declare.

REFERENCES
1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet Lond Engl 2022; S0140-6736(21):02796–2803.

2. Honardoost M, Janani L, Aghili R, et al. The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis. Cerebrovasc Dis Basel Switz 2021; 50(2):132–40.

3. Hobohm L, Sagoschen I, Barco S, et al. Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample. Viruses 2022 Jan 28;14(2):275.

4. Chaturvedi A, Kanwar M, Chandrika P, et al. National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations - Analysis of the National Inpatient Sample Database. Int J Cardiol 2020;319:131–8.

5. Harder EM, Small AM, Fares WH. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir Med 2020;161:105850.

6. Horn EM, Chakinala M, Oudiz R, et al. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm Circ 2020;10(2). 204589402092279.

7. Scuri P, Iacovoni A, Abete R, et al. An unexpected recovery of patients with pulmonary arterial hypertension and SARS-CoV-2 pneumonia: a case series. Pulm Circ 2020 Jul;10(3). 204589402095658.

8. Nucic J, Perez-Olivares C, Segura de la Cal T, et al. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev Esp Cardiol Engl Ed 2020;73(9):775–8.

9. Montani D, Certain MC, Weatherald J, et al. COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. Am J Respir Crit Care Med 2022.

10. Belge C, Quarc R, Godinas L, et al. COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Res 2020;6(4):00520–2020.

11. Lee JD, Burger CD, Delossantos GB, et al. A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. Ann Am Thorac Soc 2020;17(12):1576–82.

12. Farmakis IT, Karyofyllis P, Frantzeskaki F, et al. Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmonary hypertension registry (HOPE). Hell J Cardiol HJC Hell Kardiologike Epitheorese 2022;64:93–6.

13. Badagliacca R, Papa S, D’Alto M, et al. The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? Eur Respir J 2022;2102276.

14. Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health 2020;5(8):e444–51.

15. Therapeutics and COVID-19: living guideline [Internet]. 2020. https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline. [Accessed 25 February 2022].

16. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019;53(1):1801906.

17. Puk O, Nowacka A, Smulewicz K, et al. Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review. Biomed Pharmacother 2022;146:112592.
18. Moezinia CJ, Ji-Xu A, Azari A, et al. Iloprost for COVID-19-related vasculopathy. Lancet Rheumatol 2020;2(10):e582–3.
19. Sonti R, Pike CW, Cobb N. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19. J Intensive Care Med 2021;36(3): 327–33.
20. Matthews L, Baker L, Ferrari M, et al. Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19. J Intensive Care Med 2022. 8850666221086521.
21. Castiglione L, Droppa M. Pulmonary Hypertension and COVID-19. Hamostaseologie 2021.
22. McFadyen C, Garfield B, Mancio J, et al. Use of sildenafil in patients with severe COVID-19 pneumonia. Br J Anaesth 2022;(22):S0007–912, 00186-6.
23. Wieteska-Mi1ek M, Szmit S, Florczyk M, et al. COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination. Vaccines 2021;9(12):1395.
24. Galić N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Heart J 2016;37(1):67–119.
25. Wesley Milks M, Sahay S, Benza RL, et al. Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review. J Heart Lung Transplant 2021;40(3):172–82.
26. Ryan JJ, Melendres-Groves L, Zamanian RT, et al. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ 2020;10(2). 204589402092015.
27. Tamura Y, Takeyasu R, Furukawa A, et al. How COVID-19 Affected the Introduction of Telemedicine and Patient Reported Outcomes Among Patients With Pulmonary Hypertension — A Report From a Referral Center in Japan. Circ Rep 2020;2(9): 526–30.
28. Wieteska-Milek M, Szmit S, Florczyk M, et al. Fear of COVID-19, Anxiety and Depression in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the Pandemic. J Clin Med 2021;10(18):4195.
29. Godinas L, Iyer K, Meszaros G, et al. PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet J Rare Dis 2021;16(1):196.
30. Halawa S, Pullamsetti SS, Bangham CRM, et al. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat Rev Cardiol 2022;19(5):314–31.
31. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27(4):601–15.
32. Suzuki YJ, Nikolaenko SI, Shults NV, et al. COVID-19 patients may become predisposed to pulmonary arterial hypertension. Med Hypotheses 2021;147: 110483.
33. Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart Br Card Soc 2020;106(17):1324–31.
34. Norderfeldt J, Liliequist C, Frostell C, et al. Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care. Acta Anaesthesiol Scand 2021;65(6):761–9.
35. Caravita S, Baratto C, Di Marco F, et al. Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization. Eur J Heart Fail 2020;22(12):2228–37.
36. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022;28(3): 583–90.
37. Katsoularis I, Fonseca-Rodrı́guez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ 2022;377:e069590.
38. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75(23):2950–73.
39. Sulica R, Cefai F, Motschwiller C, et al. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics 2021;11(1):128.